Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial

Autor: S. Dubey, J. D. Naik, S. Chan, Jørn Herrstedt, R. Davis, A. H. Jakobsen, J. von Pawel, Marianne Ewertz, Karin Jordan, Meinolf Karthaus, Yvonne Summers, G. Fox

Publikováno v: Herrstedt, J, Summers, Y, Jordan, K, von Pawel, J, Jakobsen, A H, Ewertz, M, Chan, S, Naik, J D, Karthaus, M, Dubey, S, Davis, R & Fox, G M 2019, ' Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy : a randomised, double-blind, placebo-controlled, dose-ranging trial ', Supportive Care in Cancer, vol. 27, no. 7, pp. 2699-2705 . https://doi.org/10.1007/s00520-018-4564-8

Purpose: Chemotherapy-induced nausea and vomiting (CINV) remain significant clinical problems, especially in the delayed phase (24–120 h after chemotherapy). Amisulpride is a dopamine D2/D3-receptor antagonist previously shown to be an effective in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e384e8507e3d1034b087c7e9b5cff64c
https://doi.org/10.1007/s00520-018-4564-8

Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC

Autor: J. von Pawel, Daniel S. Chen, Pei He, Marcus Ballinger, Gandara, DR[Gandara, D. R.], Carlos H. Barrios, Fortunato Ciardiello, Alan Sandler, Toyoaki Hida, Daniel Waterkamp, Shirish M. Gadgeel, Diego Cortinovis, Joseph W. Leach, M Cobo Dols, W. Schütte, Fabrice Barlesi, Dariusz M. Kowalski, Achim Rittmeyer, Kwan Park, J Polikoff

Publikováno v: Pneumologie. 71:S1-S125

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5e7adf726719cc6998078fd9d71609c0
https://doi.org/10.1055/s-0037-1598278

Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study

Autor: Paul Conkling, J-Y. Han, M. Cobo, M. Gandhi, Denis Moro-Sibilot, Louis Fehrenbacher, Wei Yu, Rodolfo Bordoni, Hina Patel, Marcin Kowanetz, Alan Sandler, David R. Gandara, Kwang Bo Park, C. Matheny, J. von Pawel, Achim Rittmeyer, Marcus Ballinger, Toyoaki Hida, Miyako Satouchi

Publikováno v: European journal of cancer (Oxford, England : 1990). 107

Background Atezolizumab (anti–programmed death-ligand 1 [PD-L1]) received approval from the US Food and Drug Administration and European Medicines Agency for previously treated advanced non–small-cell lung cancer based on OAK—a randomised, phas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0b7dfcd829899579455b39aa9e2ca0c
https://pubmed.ncbi.nlm.nih.gov/30562710

A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer

Autor: G. Zalcman, J. von Pawel, Fabrice Barlesi, Enric Carcereny, I. Garcia-Ribas, Enriqueta Felip, Armando Santoro, Martin Reck, Silvia Novello, Federico Cappuzzo, G.V. Scagliotti, David Ferry, Julien Mazieres, Benjamin Besse, J-C. Soria

Publikováno v: Annals of Oncology. 25:2156-2162

Background Iniparib is a novel anticancer agent initially considered a poly (ADP-ribose) polymerase (PARP) inhibitor, but subsequently shown to act via non-selective protein modification through cysteine adducts. This randomized phase II study invest

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c8ca25982fc1ecfb44ac9c8433a8ef2
https://doi.org/10.1093/annonc/mdu384